Taiwanese Journal of Obstetrics and Gynecology
Volume 46, Issue 3 , Pages 222-229, September 2007

Microarray Analysis of Gene Expression of Cancer to Guide the Use of Chemotherapeutics

  • Tzu-Hao Wang

      Affiliations

    • Department of Obstetrics and Gynecology, Lin-Kou Medical Center, Chang Gung Memorial Hospital, Chang Gung University, Tao-Yuan, Taiwan
    • Genomic Medicine Research Core Laboratory, Chang Gung Memorial Hospital, Tao-Yuan, Taiwan
    • Corresponding Author InformationCorrespondence to: Dr Tzu-Hao Wang, Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Chang Gung University, Tao-Yuan 333, Taiwan
    • ,
  • Angel Chao

      Affiliations

    • Department of Obstetrics and Gynecology, Lin-Kou Medical Center, Chang Gung Memorial Hospital, Chang Gung University, Tao-Yuan, Taiwan

Accepted 9 August 2007.

Article Outline

Summary 

The beauty of microarray analysis of gene expression (MAGE) is that it can be used to discover some genes that were previously thought to be unrelated to a physiologic or pathologic event. During the period from 1999 to 2007, applications of MAGE in cancer investigation have shifted from molecular profiling, identifying previously undiscovered cancer types, predicting outcomes of cancer patients, revealing metastasis signatures of solid tumors, to guiding the use of therapeutics. The roles of cancer genomic signatures have evolved through three phases. In the first phase, genomic signatures were described in stored cancer specimens and dubbed as molecular portraits of cancer. When gene expression profiles were carefully correlated with sufficient clinical information of cancer patients, new subgroups of cancers with distinct outcomes were revealed. In studies of the second phase, validation of cancer signatures was emphasized and commonly performed with independent groups of cancer specimens or independent data set. In the third phase, cancer genomic signatures have been further expanded beyond depicting the molecular portrait of cancer to predicting patient outcomes and guiding the use of cancer therapeutics. Cancer genomic signatures have become an essential part of a new generation of cancer clinical trials. It is advocated that, in future clinical trials of cancer therapy, the cancer specimens of each participant should be tested for currently available predictor genomic signatures, so that the most effective treatment with the least adverse effects for each patient can be identified. Then, participants can be triaged to an appropriate study group.

Key Words:  cancer therapeutics , clinical application , gene expression , genomic signatures , microarrays

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Wang TH , Lee YS , Chen ES , et al.   Establishment of cDNA microarray analysis at the Genomic Medicine Research Core Laboratory (GMRCL) of Chang Gung Memorial Hospital . Chang Gung Med J . 2004;27:243–260
  2. Chao A, Wang TH, Lai CH. Overview of microarray analysis of gene expression and its applications to cervical cancer investigation. Taiwan J Obstet Gynecol 2007 (In press).
  3. Lee YS , Chen CH , Chao A , et al.   Molecular signature of clinical severity in recovering patients with severe acute respiratory syndrome coronavirus (SARS-CoV) . BMC Genomics . 2005;6:132
  4. Chao A , Wang TH , Lee YS , et al.   Molecular characterization of adenocarcinoma and squamous carcinoma of the uterine cervix using microarray analysis of gene expression . Int J Cancer . 2006;119:91–98
  5. Wang TH , Chan YH , Chen CW , et al.   Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways . Oncogene . 2006;25:4857–4866
  6. Tsai MS, Hwang SM, Chen KD, et al. Functional network analysis on the transcriptomes of mesenchymal stem cells derived from amniotic fluid, amniotic membrane, cord blood, and bone marrow. Stem Cells 2007 (In press).
  7. Tan PK , Downey TJ , Spitznagel EL , et al.   Evaluation of gene expression measurements from commercial microar-ray platforms . Nucleic Acids Res . 2003;31:5676–5684
  8. Yauk CL , Berndt ML , Williams A , Douglas GR . Comprehensive comparison of six microarray technologies . Nucleic Acids Res . 2004;32:e124
  9. Carter SL , Eklund AC , Mecham BH , Kohane IS , Szallasi Z . Redefinition of Affymetrix probe sets by sequence overlap with cDNA microarray probes reduces cross-platform inconsistencies in cancer-associated gene expression measurements . BMC Bioinformatics . 2005;6:107
  10. Wang H , He X , Band M , Wilson C , Liu L . A study of inter-lab and inter-platform agreement of DNA microarray data . BMC Genomics . 2005;6:71
  11. Fortunel NO , Otu HH , Ng HH , et al.   Comment on “;‘Stemness’: transcriptional profiling of embryonic and adult stem cells” and “a stem cell molecular signature” . Science . 2003;302:393; author reply 393.
  12. Marshall E . Getting the noise out of gene arrays . Science . 2004;306:630–631
  13. Strauss E . Arrays of hope . Cell . 2006;127:657–659
  14. Tong W , Lucas AB , Shippy R , et al.   Evaluation of external RNA controls for the assessment of microarray performance . Nat Biotechnol . 2006;24:1132–1139
  15. Canales RD , Luo Y , Willey JC , et al.   Evaluation of DNA microarray results with quantitative gene expression platforms . Nat Biotechnol . 2006;24:1115–1122
  16. Patterson TA , Lobenhofer EK , Fulmer-Smentek SB , et al.   Performance comparison of one-color and two-color platforms within the MicroArray Quality Control (MAQC) project . Nat Biotechnol . 2006;24:1140–1150
  17. Shi L , Reid LH , Jones WD , et al. , for MAQC Consortium    The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements . Nat Biotechnol . 2006;24:1151–1161
  18. Guo L , Lobenhofer EK , Wang C , et al.   Rat toxicogenomic study reveals analytical consistency across microarray platforms . Nat Biotechnol . 2006;24:1162–1169
  19. Liu ET , Karuturi KR . Microarrays and clinical investigations . N Engl J Med . 2004;350:1595–1597
  20. Grimwade D , Haferlach T . Gene-expression profiling in acute myeloid leukemia . N Engl J Med . 2004;350:1676–1678
  21. Febbo PG , Kantoff PW . Noise and bias in microarray analysis of tumor specimens . J Clin Oncol . 2006;24:3719–3721
  22. Rhodes DR , Chinnaiyan AM . Integrative analysis of the cancer transcriptome . Nat Genet . 2005;37(Suppl):S31–S37
  23. Segal E , Friedman N , Kaminski N , Regev A , Koller D . From signatures to models: understanding cancer using microar-rays . Nat Genet . 2005;37(Suppl):S38–S45
  24. Eisen MB , Spellman PT , Brown PO , Botstein D . Cluster analysis and display of genomewide expression patterns . Proc Natl Acad Sci USA . 1998;95:14863–14868
  25. Rhodes DR , Yu J , Shanker K , et al.   Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression . Proc Natl Acad Sci USA . 2004;101:9309–9314
  26. Harris MA , Clark J , Ireland A , et al. , for Gene Ontology Consortium    The Gene Ontology (GO) database and informatics resource . Nucleic Acids Res . 2004;32(Database issue):D258–D261
  27. Rhodes DR , Kalyana-Sundaram S , Mahavisno V , Barrette TR , Ghosh D , Chinnaiyan AM . Mining for regulatory programs in the cancer transcriptome . Nat Genet . 2005;37:579–583
  28. Weinmann AS , Yan PS , Oberley MJ , Huang TH , Farnham PJ . Isolating human transcription factor targets by coupling chromatin immunoprecipitation and CpG island microar-ray analysis . Genes Dev . 2002;16:235–244
  29. Odom DT , Zizlsperger N , Gordon DB , et al.   Control of pancreas and liver gene expression by HNF transcription factors . Science . 2004;303:1378–1381
  30. Mootha VK , Lindgren CM , Eriksson KF , et al.   PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes . Nat Genet . 2003;34:267–273
  31. Segal E , Friedman N , Koller D , Regev A . A module map showing conditional activity of expression modules in cancer . Nat Genet . 2004;36:1090–1098
  32. Golub TR , Slonim DK , Tamayo P , et al.   Molecular classification of cancer: class discovery and class prediction by gene expression monitoring . Science . 1999;286:531–537
  33. Perou CM , Sorlie T , Eisen MB , et al.   Molecular portraits of human breast tumours . Nature . 2000;406:747–752
  34. Alizadeh AA , Eisen MB , Davis RE , et al.   Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling . Nature . 2000;403:503–511
  35. van't Veer LJ , Dai H , van de Vijver MJ , et al.   Gene expression profiling predicts clinical outcome of breast cancer . Nature . 2002;415:530–536
  36. Shipp MA , Ross KN , Tamayo P , et al.   Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning . Nat Med . 2002;8:68–74
  37. Ramaswamy S , Ross KN , Lander ES , Golub TR . A molecular signature of metastasis in primary solid tumors . Nat Genet . 2003;33:49–54
  38. Potti A , Dressman HK , Bild A , et al.   Genomic signatures to guide the use of chemotherapeutics . Nat Med . 2006;12:1294–1300
  39. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes . N Engl J Med . 2004;350:1828–1837
  40. Perou CM , Jeffrey SS , van de Rijn M , et al.   Distinctive gene expression patterns in human mammary epithelial cells and breast cancers . Proc Natl Acad Sci USA . 1999;96:9212–9217
  41. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project . Blood . 1997;89:3909–3918
  42. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group . Lancet . 1998;352:930–942
  43. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group . Lancet . 1998;351:1451–1467
  44. Liotta LA , Kohn EC . Cancer's deadly signature . Nat Genet . 2003;33:10–11
  45. Bullinger L , Dohner K , Bair E , et al.   Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia . N Engl J Med . 2004;350:1605–1616
  46. Valk PJ , Verhaak RG , Beijen MA , et al.   Prognostically useful gene-expression profiles in acute myeloid leukemia . N Engl J Med . 2004;350:1617–1628
  47. Michiels S , Koscielny S , Hill C . Prediction of cancer outcome with microarrays: a multiple random validation strategy . Lancet . 2005;365:488–492
  48. Sorlie T , Perou CM , Tibshirani R , et al.   Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications . Proc Natl Acad Sci USA . 2001;98:10869–10874
  49. van de Vijver MJ , He YD , van't Veer LJ , et al.   A gene-expression signature as a predictor of survival in breast cancer . N Engl J Med . 2002;347:1999–2009
  50. Chang HY , Nuyten DS , Sneddon JB , et al.   Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival . Proc Natl Acad Sci USA . 2005;102:3738–3743
  51. Chang HY , Sneddon JB , Alizadeh AA , et al.   Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds . PLoS Biol . 2004;2:E7
  52. Rosenwald A , Wright G , Chan WC , et al. , for the Lymphoma/Leukemia Molecular Profiling Project    The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma . N Engl J Med . 2002;346:1937–1947
  53. Fan C , Oh DS , Wessels L , et al.   Concordance among gene-expression-based predictors for breast cancer . N Engl J Med . 2006;355:560–569
  54. Bild AH , Yao G , Chang JT , et al.   Oncogenic pathway signatures in human cancers as a guide to targeted therapies . Nature . 2006;439:353–357
  55. Breathnach OS , Freidlin B , Conley B , et al.   Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results . J Clin Oncol . 2001;19:1734–1742
  56. Staunton JE , Slonim DK , Coller HA , et al.   Chemosensitivity prediction by transcriptional profiling . Proc Natl Acad Sci USA . 2001;98:10787–10792
  57. Gyorffy B, Surowiak P, Kiesslich O, Denkert C, Schafer R, Dietel M, et al. Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations . Int J Cancer . 2006;118:1699–1712
  58. Herbst RS , Lippman SM . Molecular signatures of lung cancer—toward personalized therapy . N Engl J Med . 2007;356:76–78
  59. Potti A , Mukherjee S , Petersen R , et al.   A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer . N Engl J Med . 2006;355:570–580
  60. Dressman HK , Berchuck A , Chan G , et al.   An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer . J Clin Oncol . 2007;25:517–525

PII: S1028-4559(08)60024-8

doi:10.1016/S1028-4559(08)60024-8

Taiwanese Journal of Obstetrics and Gynecology
Volume 46, Issue 3 , Pages 222-229, September 2007

Article Tools